secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001213900-23-088069
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax receives Nasdaq deficiency notice for delayed Q3 10-Q filing; 60 days to submit plan
--------------------------------------------------------------------------------

- Nasdaq notified Virpax on Nov 16, 2023 for non-compliance due to late Q3 10-Q filing.
- Delay stems from evaluating Delaware court decision in litigation with Sorrento Therapeutics and Scilex Pharmaceuticals.
- Company has until Jan 16, 2024 to submit a plan; Nasdaq can extend to May 13, 2024.
- Listing unaffected immediately; no guarantee of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023088069/0001213900-23-088069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023088069/ea188634-8k_virpaxpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-088069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer